Loading Calculator...
Please wait a moment
Please wait a moment
Assess Parkinson's disease severity using motor symptoms evaluation. This simplified assessment helps determine disease stage based on the Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn-Yahr staging system.
Rate each symptom from 0-4 (0=None, 1=Slight, 2=Mild, 3=Moderate, 4=Severe)
0: No tremor
1: Slight, present occasionally
2: Mild, present most of the time
3: Moderate amplitude, present most of time
4: Marked amplitude, present most of time
0: No rigidity
1: Slight or only with activation
2: Mild to moderate rigidity
3: Marked rigidity, full range of motion achieved
4: Severe rigidity, difficult to achieve full range
0: Normal speed and movement
1: Slight slowness, reduced arm swing
2: Mild slowness and reduced movement
3: Moderate slowness, occasional hesitation
4: Severe slowness, frequent hesitation or freezing
0: Normal balance
1: Recovers unaided from pull test
2: Would fall if not caught by examiner
3: Very unstable, loses balance spontaneously
4: Cannot stand without assistance
0: Normal gait
1: Walks slowly, may shuffle, no festination
2: Walks with difficulty, little or no assistance
3: Severe gait disturbance, requires assistance
4: Cannot walk, even with assistance
| Stage | Description | Characteristics |
|---|---|---|
| Stage 1 | Unilateral involvement | Symptoms on one side only, minimal functional impairment |
| Stage 1.5 | Unilateral + axial | One side plus neck and spine involvement |
| Stage 2 | Bilateral involvement | Both sides affected, balance still maintained |
| Stage 2.5 | Mild bilateral | Bilateral with recovery on pull test |
| Stage 3 | Postural instability | Balance impaired, physically independent |
| Stage 4 | Severe disability | Can stand/walk unassisted but severely incapacitated |
| Stage 5 | Wheelchair/bed bound | Cannot stand or walk without assistance |
Parkinson's disease is a progressive neurodegenerative disorder that affects movement. It occurs when nerve cells in the brain that produce dopamine become impaired or die. Dopamine is a neurotransmitter that helps control movement and coordination.
Medications: Levodopa/carbidopa (Sinemet) is the gold standard. Other options include dopamine agonists (pramipexole, ropinirole), MAO-B inhibitors (rasagiline, selegiline), COMT inhibitors (entacapone), and anticholinergics. Treatment is individualized based on symptoms, age, and side effects.
Advanced Therapies: Deep brain stimulation (DBS) can be highly effective for motor fluctuations. Continuous dopaminergic therapy options include apomorphine infusion and duopa (intestinal levodopa/carbidopa gel).
Non-pharmacological: Physical therapy, occupational therapy, speech therapy, and exercise programs (especially aerobic and resistance training) are essential components of comprehensive care.
The Unified Parkinson's Disease Rating Scale (UPDRS) is the most commonly used rating scale for Parkinson's disease. It assesses mental functioning, behavior, mood, activities of daily living, and motor function. The complete UPDRS has multiple parts and takes 15-30 minutes to administer. This calculator uses a simplified motor assessment.
Parkinson's disease progression varies significantly between individuals. Some people remain stable for years with medication, while others progress more rapidly. Regular monitoring, medication adjustments, and comprehensive multidisciplinary care can optimize quality of life throughout the disease course.
The exact cause is unknown, but it involves the loss of dopamine-producing neurons in the substantia nigra region of the brain. Contributing factors may include genetics (10-15% have family history), environmental toxins, age, and oxidative stress. Most cases are idiopathic (no known cause).
Diagnosis is clinical, based on medical history and neurological examination. No single test confirms Parkinson's. Doctors look for at least two of the four cardinal motor signs (tremor, rigidity, bradykinesia, postural instability). DaTscan imaging can support diagnosis but isn't required. Response to levodopa medication also helps confirm diagnosis.
There's no universal rule. Medication is typically started when symptoms interfere with daily activities or quality of life. Some doctors delay levodopa due to concerns about long-term complications (dyskinesias), while others start early. The decision is individualized, considering age, symptom severity, functional impact, and patient preference.
The Hoehn-Yahr scale is a simple 5-stage system describing disease progression from unilateral to bilateral involvement to severe disability. The UPDRS is more comprehensive, assessing multiple domains including mental function, daily activities, and detailed motor examination. Both are used together for complete assessment.
Yes, exercise is crucial for managing Parkinson's. Studies show that regular aerobic exercise, strength training, balance exercises, and activities like boxing, dancing, and tai chi can improve motor symptoms, balance, mood, and quality of life. Exercise may also have neuroprotective effects. Aim for 150 minutes per week of moderate-intensity activity.
DBS is a surgical treatment where electrodes are implanted in specific brain regions (usually subthalamic nucleus or globus pallidus). The electrodes deliver electrical pulses that help regulate abnormal brain activity. DBS is typically considered for patients with motor fluctuations, dyskinesias, or inadequate symptom control despite optimized medications. It can significantly improve quality of life but doesn't stop disease progression.
Motor fluctuations are changes in symptom control related to medication timing. "Wearing off" means symptoms return before the next dose. "On-off" fluctuations are unpredictable changes between good control ("on") and poor control ("off"). Dyskinesias are involuntary movements caused by long-term levodopa use. Both can be managed with medication adjustments or advanced therapies.
Progression varies widely. Some people progress slowly over decades, while others advance more rapidly. Younger age at onset often means slower progression. On average, it takes about 10-15 years to progress from stage 1 to stage 5. However, with modern treatments, many patients maintain good quality of life for many years. Regular neurologist follow-up and proactive management are key.
Montreal Cognitive Assessment for cognitive screening
Screen for diabetic peripheral neuropathy
Track seizure control and driving eligibility
Evaluate stroke severity using NIH Stroke Scale
Assess elderly fall risk and prevention strategies
Screen for depression using PHQ-9 scale
Medical Disclaimer: This calculator is for educational purposes only and provides a simplified assessment. It should not replace professional medical evaluation. Parkinson's disease diagnosis and management requires comprehensive assessment by a neurologist or movement disorder specialist. The UPDRS and Hoehn-Yahr scales should be administered by trained healthcare professionals.